Influence of Maternal Antibodies on Efficacy of Porcine Circovirus Type 2 (PCV2) Vaccination To Protect Pigs from Experimental Infection with PCV2

Opriessnig, Tanja; Patterson, Abby R.; Elsener, Johanne; Meng, Xiang‐Jin; Halbur, Patrick G.

doi:10.1128/cvi.00416-07

Cited by 91 publications

(67 citation statements)

References 19 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several research groups have studied the efficacy of commercial PCV2 vaccines in pigs singularly infected with PCV2 (30,31) or in pigs concurrently infected with multiple pathogens (33,42). In all previous studies, vaccination was done according to the manufacturer's label instructions.…”

Section: Discussionmentioning

confidence: 99%

Studies on Porcine Circovirus Type 2 Vaccination of 5-Day-Old Piglets

O'Neill

Shen

Lin

et al. 2011

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

Porcine circovirus type 2 (PCV2) vaccines have become widely used since they became available in 2006. It is not uncommon for producers to use PCV2 vaccines in pigs younger than what is approved by manufacturers. The objective of this study was to determine the efficacy of a chimeric and a subunit PCV2 vaccine administered at 5 or 21 days of age. Forty-eight PCV2-naïve piglets were randomly divided into six groups of eight pigs each. Vaccination was done at day 5 or day 21, followed by triple challenge with PCV2, porcine parvovirus (PPV), and porcine reproductive and respiratory syndrome virus (PRRSV) at day 49. Vaccinated pigs seroconverted to PCV2 approximately 14 days postvaccination and had a detectable neutralizing antibody response by 21 days postvaccination regardless of age at vaccination. At day 49, the pigs vaccinated with the chimeric vaccine had significantly higher levels of neutralizing antibodies than the pigs vaccinated with the subunit vaccine. After challenge, vaccinated pigs had significantly decreased levels of PCV2 viremia and a decreased prevalence and severity of microscopic lesions compared to the positive-control group, which had severe lymphoid lesions associated with abundant PCV2 antigen, compatible with PCV-associated disease. The results of this study indicate that, under the conditions of this study, vaccination of PCV2-naïve pigs at day 5 or day 21 resulted in development of a detectable humoral immune response and provided reduction or complete protection against PCV2 viremia and PCV2-associated lesions after triple challenge with PCV2, PPV, and PRRSV.

show abstract

Section: Discussionmentioning

confidence: 99%

Studies on Porcine Circovirus Type 2 Vaccination of 5-Day-Old Piglets

O'Neill

Shen

Lin

et al. 2011

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…These data suggest that PCV2 viremia in the blood is not reflected in the levels of PCV2 antibodies in the blood. It has been reported that a reduced PCV2 load in the serum is unrelated to the serum antibody response to the PCV2 vaccine (16,18). Boars in the vaccinated challenged and nonvaccinated challenged group had detectable serum levels of anti-PCV2 IgG, indicating successful vaccination and/or challenge.…”

Section: Discussionmentioning

confidence: 92%

“…PCV2 vaccines decrease the PCV2 load in the serum and reduce PCV2 shedding in nasal and fecal samples in conventional pigs (5). Commercial vaccines were shown to be able to control two of the multiple disease entities, known as PMWS and PRDC (2,4,5,16,18). To our knowledge, this is the first application of a PCV2 vaccine in boars to determine its effect on PCV2 shedding in the semen.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of an Inactivated Porcine Circovirus Type 2 (PCV2) Vaccine on PCV2 Virus Shedding in Semen from Experimentally Infected Boars

Seo

Han

Kim

et al. 2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

The objective of the present study was to determine the effect of an inactivated porcine circovirus type 2 (PCV2) vaccine on PCV2b virus shedding in the semen of experimentally infected boars by measuring the immunological response and the PCV2b DNA load in blood and semen. Twelve boars were randomly divided into three groups. The boars in group 1 (n ‫؍‬ 4) were immunized with an inactivated PCV2 vaccine and were challenged with PCV2b. The boars in group 2 (n ‫؍‬ 4) were only challenged with PCV2b. The boars in group 3 (n ‫؍‬ 4) served as negative controls. The number of PCV2 genome copies of PCV2 in the serum and semen were significantly lower in vaccinated challenged boars than in nonvaccinated challenged boars at 7, 10, 14, 21, 32, 35, 42, 49, and 60 days postinoculation. The number of PCV2b genomes in the semen correlated with the number of PCV2b genomes in the blood in both vaccinated challenged (R ‫؍‬ 0.714) and nonvaccinated challenged (R ‫؍‬ 0.861) boars. The results of the present study demonstrate that the inactivated PCV2 vaccine significantly decreases the amount of PCV2b DNA shedding in semen from vaccinated boars after experimental infection with PCV2b.Porcine circovirus type 2 (PCV2) is associated with a number of diseases and syndromes collectively referred to as porcine circovirus-associated disease (PCVAD), which includes postweaning multisystemic wasting disease (PMWS), porcine dermatitis and nephropathy syndrome (PDNS), reproductive failure, porcine respiratory disease complex (PRDC), and exudative epidermitis (3).Several commercial PCV2 vaccines are currently available in the global market. All PCV2 vaccines have been administered to either sows or piglets (2,5,16,18). Commercial PCV2 vaccines are able to reduce the PCV2 load in the serum and reduce PCV2 shedding in nasal and fecal samples in conventional pigs (5,15,16,18). Recently, it has also been reported that vaccination against PCV2 in naturally infected boars can decrease the duration of viral shedding in semen (1). These data strongly imply that vaccination against PCV2 may reduce the subsequent shedding of PCV2 in the semen of boars. Therefore, the objective of the present study was to determine the effect of PCV2 vaccination on the shedding of the PCV2 virus in the semen of experimentally infected boars. MATERIALS AND METHODSCommercial vaccine and PCV2 inoculum. The commercial inactivated tissue homogenate PCV2 vaccine based on PCV2 genotype 2b, CircoPrime (Komipharm International Company Ltd., Shiheung-shi, Kyongki-do, Republic of Korea), was used in this study. It was administered intramuscularly in two 2.0-ml doses separated by 3 weeks.The PCV2 strain (PCV2 genotype b) isolated from the superficial inguinal lymph node of a field case of PMWS was used as the inoculum. The virus was propagated in PCV-free PK15 cells to a titer of 10 5 50% tissue culture infective doses (TCID 50 s)/ml.Experimental design. At 8 months of age, 12 purebred, male, Landrace pigs were purchased from a commercial farm. All boars were negative for PCV2 and...

show abstract

“…Assays are organized by submitting laboratory and type of assay; indirect fluorescent antibody tests (IFA), in-house enzyme-linked immunosorbent assays (ELISA), and commercially available (Serelisa g [S] or Ingezim f [I]) ELISAs. tal studies, 14 there were likely consistently high levels of antibodies present at this point, which enhanced uniformity in test results in comparison with samples taken from animals shortly after PCV-2 infection as evident in the kappa values (poor to almost perfect) obtained on trial day 14.…”

Section: Discussionmentioning

confidence: 99%

Interlaboratory Comparison of Porcine Circovirus-2 Indirect Immunofluorescent Antibody Test and Enzyme-Linked Immunosorbent Assay Results on Experimentally Infected Pigs

et al. 2011

View full text Add to dashboard Cite

Abstract. A blinded interlaboratory assessment of the diagnostic agreement and accuracy of serologic tests for routine detection of antibodies against Porcine circovirus-2 (PCV-2), including indirect fluorescent antibody tests (IFATs) and enzyme-linked immunosorbent assays (ELISAs) was conducted in 7 North American laboratories. Serum samples were collected weekly, on trial days 0, 7, 14, 21, 28, 35, 42, and 49, from the following groups of animals: 1) negative controls (n 5 7), 2) PCV-2a (n 5 8), 3) PCV-2b (n 5 8), 4) PCV-1 (n 5 8), 5) PCV-2 vaccine A (n 5 8; IngelvacH CircoFLEX TM ), 6) PCV-2 vaccine B (n 5 8; CircumventH PCV2), and 7) PCV-2 vaccine C (n 5 8; SuvaxynH PCV2 One Dose). Results from each laboratory were analyzed by kappa and receiver operating characteristic (ROC) analysis. Kappa analysis indicated that, by trial day 49, IFATs had almost perfect agreement, in-house ELISAs had fair to almost perfect agreement, and commercially available anti-PCV-2 immunoglobulin G ELISAs (I or S) had moderate to substantial agreement. From trial days 14-49, the area under the ROC curve for the 2 laboratories that offered IFATs, the 4 laboratories that offered in-house ELISAs, and the 3 laboratories that used commercially available ELISAs ranged from 0.94 to 1.00, 0.72 to 1.00, and 0.95 to 1.00, respectively. However, test sensitivities varied based on laboratory-specific cutoffs that were used to dichotomize test results.

show abstract

Influence of Maternal Antibodies on Efficacy of Porcine Circovirus Type 2 (PCV2) Vaccination To Protect Pigs from Experimental Infection with PCV2

Cited by 91 publications

References 19 publications

Studies on Porcine Circovirus Type 2 Vaccination of 5-Day-Old Piglets

Studies on Porcine Circovirus Type 2 Vaccination of 5-Day-Old Piglets

Effects of an Inactivated Porcine Circovirus Type 2 (PCV2) Vaccine on PCV2 Virus Shedding in Semen from Experimentally Infected Boars

Interlaboratory Comparison of Porcine Circovirus-2 Indirect Immunofluorescent Antibody Test and Enzyme-Linked Immunosorbent Assay Results on Experimentally Infected Pigs

Contact Info

Product

Resources

About